Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The objectives of the study are to evaluate the safety, tolerability, and effectiveness of
NUEDEXTA capsules containing 20 mg DM (Dextromethorphan)/10 mg Q (Quinidine) for treatment of
Pseudobulbar Affect (PBA) in patients with prevalent conditions such as dementia, stroke, and
traumatic brain injury (TBI)over a 12 week period.